1
Roger D Tung, Scott L Harbeson, David D Deininger, Mark A Murcko, Govinda R Bhisetti, Luc J Farmer: Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. Vertex Pharmaceuticals Incorporated, James F Haley, Lisa A Dixon, Fish & Neave, July 24, 2001: US06265380 (85 worldwide citation)

The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhi ...


2
Roger D Tung, Scott L Harbeson, David D Deininger, Mark A Murcko, Govinda R Bhisetti, Luc J Farmer: Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. Vertex Pharmaceuticals Incorporated, James F Haley Jr, Kyumin K Lee, Fish & Neave, September 9, 2003: US06617309 (65 worldwide citation)

The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhi ...


3
Cottrell Kevin M, Perni Robert B, Pitlik Janos: Inhibitors of serine proteases, particularly hcv ns3-ns4a protease. Vertex Pharmaceuticals Incoporated, Cottrell Kevin M, Perni Robert B, Pitlik Janos, HALEY James F Jr, April 28, 2005: WO/2005/037860 (63 worldwide citation)

The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus a ...


4
Cottrell Kevin M, Maxwell John, Tang Qing, Grillot Anne Laure, Le, Tiran Arnaud, Perola Emanuele: Inhibitors of serine proteases. Vertex Pharmaceuticals Incorporated, Cottrell Kevin M, Maxwell John, Tang Qing, Grillot Anne Laure, Le, Tiran Arnaud, Perola Emanuele, O BRIEN Jonathan P, March 1, 2007: WO/2007/025307 (53 worldwide citation)

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.


5
Roger D Tung, Scott L Harbeson, David D Deininger, Mark A Murcko, Govinda R Bhisetti, Luc J Farmer: Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. Vertex Pharmaceuticals Incorporated, Ropes & Gray, James F Haley Jr, David A Roise, June 17, 2008: US07388017 (49 worldwide citation)

The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhi ...


6
Kevin M Cottrell, Robert B Perni, Janos Pitlik: Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases. Vertex Pharmaceuticals Incorporated, Susan C Kelly, April 24, 2007: US07208600 (45 worldwide citation)

The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus an ...


7
Cottrell Kevin M, Perni Robert P, Pitlik Janos, Schairer Wayne C: Inhibitors of serine proteases, particularly hcv ns3-ns4a protease. Vertex Pharmaceuticals Incorporated, Cottrell Kevin M, Perni Robert P, Pitlik Janos, Schairer Wayne C, BADIA Michael C, March 31, 2005: WO/2005/028502 (45 worldwide citation)

The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are use ...


8
Janos Pitlik, Kevin M Cottrell, Luc J Farmer, Robert B Perni, Lawrence F Courtney, John H van Drie, Mark A Murcko: Inhibitors of serine proteases, particularly HCV NS3-NS4A protease. Vertex Pharmaceuticals Incorporated, Susan C Kelly, Lisa A Dixon, September 25, 2007: US07273885 (41 worldwide citation)

The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to ...


9
Campbell David Alan, Winn David T, Betancort Juan Manuel, Hepperle Michael E: Hepatitis c serine protease inhibitors and uses therefor. Phenomix Corporation, Campbell David Alan, Winn David T, Betancort Juan Manuel, Hepperle Michael E, STEFFEY Charles E, February 8, 2007: WO/2007/016476 (40 worldwide citation)

The present invention provides novel compounds which mimic peptides with a C-terminal penultimate proline, such compounds being useful as protease inhibitors, particularly as inhibitors of serine proteases, and more particularly as inhibitors of the NS3 serine protease from hepatitis C. The compound ...


10
Perni Robert B, Court John J, Britt Shawn D, Pitlik Janos, Van, Drie John H: 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease. Vertex Pharmaceuticals Incorporated, Perni Robert B, Court John J, Britt Shawn D, Pitlik Janos, Van, Drie John H, HALEY James F Jr, April 21, 2005: WO/2005/035525 (35 worldwide citation)

The present invention relates to compounds of formula I-A and I-B that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invent ...